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As evidence for the role of metal ion dysregulation in the pathogenesis of multiple CNS
disorders grows, it has become important to more precisely identify and differentiate the
biological effects of various pharmacological modulators of metal ion homeostasis. This is
particularly evident in disorders such as Alzheimer’s disease (AD), where the use of metal
chaperones (that transport metals), as opposed to chelators (which exclude metals from
biological interactions), may prove to be the ﬁrst truly disease modifying approach for this
condition. The purpose of this mini-review is to highlight the emerging notion that metal
chaperones, such as PBT2 (Prana Biotechnology), modulate a variety of critical pathways
affecting key aspects of the AD cascade to provide a more “holistic” approach to the
treatment of this disease.
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INTRODUCTION
The existing treatment options for mild to moderate Alzheimer’s
disease (AD) patients are limited to a small number of FDA-
approved pharmaceuticals, including the acetylcholinesterase
inhibitors (AChEIs) Tacrine, Donepezil, Galantamine, and
Rivastigmine. These compounds prevent the degradation of
acetylcholine (AChE) and consequently increase the concentra-
tions of this neurotransmitter in the synaptic cleft to ultimately
enhance cholinergic neurotransmission (Lleo et al., 2006). A
more recently approved medication is the N -methyl-d-aspartate
(NMDA)-receptor antagonist Memantine, which protects against
glutamate excitotoxicity (Hynd et al., 2004; Sonkusare et al., 2005;
Parsons et al., 2007) and also inhibits pathological reactions of
the tau protein (such as hyperphosphorylation and aggregation;
Li et al., 2004). The important caveat for all of these treatment
options is that none of them afford signiﬁcant long-term symp-
tomatic relief let alone provide hope for a cure. To address this,
there are numerous compounds currently in various phases of
clinical trial, and even more in preclinical development, which
are believed may offer some hope for a tangible clinical beneﬁt
in AD. We have recently published an extensive review of these
compounds (Biran et al., 2009), the majority of which target one
or both of the primary aggregating proteins implicated in the
pathogenesis of AD.
RECENT CLINICAL FAILURES IN AD
While there are amultitude of compounds currently in clinical trial
that focus on a variety of cellular targets, the majority have been
developed around the principles of the amyloid cascade hypoth-
esis (Adlard et al., 2009). It has come to pass, however, that many
of the compounds that were heralded as the shining light of AD
therapeutics have stumbled in the ﬁnal phases of clinical testing,
casting a shadow over the ﬁeld (Golde et al., 2011).
Principle among the high proﬁle failures have been;
Tramiprosate (Alzhemed), an inhibitor of Aβ oligomerization;
Tarenﬂurbil (Flurizan), a gamma-secretase modulator; Semagace-
stat (LY450139 Dihydrate), a gamma-secretase inhibitor; and
Latrepirdine (Dimebon),which has a plethora of biological effects,
but whose main biological efﬁcacy may derive from an effect
on mitochondria. These have formed the basis for several com-
mentaries (Karran et al., 2011; Sperling et al., 2011) on the
state of AD clinical trials and therapeutics, and will not be dis-
cussed here. What these failed trials do suggest, however, is that
compounds whose mechanism of action is to solely target the
beta-amyloid protein, and hence which can be considered to be
“classical approaches” (Masters and Beyreuther, 2006), may not
represent the optimal approach to the treatment of AD. Com-
pounds that provide greater and longer-lived symptomatic relief
or which represent more global/holistic approaches by targeting a
number of key aspects of the disease process may represent better
drug candidates than the classical approaches. To this end, there
is ever-increasing evidence for the efﬁcacy of metal chaperones in
the treatment of AD (Duce et al., 2011).
METAL CHAPERONES
Metal chaperones (or metallochaperones) are compounds that
function to shuttle metal ions to speciﬁc intracellular target pro-
teins. This facilitation of metal transport is distinct from metal
chelators or buffers, which function to exclude or deplete metals
from discrete cellular compartments to thereby limit biologi-
cal interactions of key metal ions. Cumulatively, however, these
processes serve to maintain tight regulatory control over cellular
metal ion homeostasis such that the intracellular concentration of
freely available metal ions (such as copper and zinc) is close to
zero.
The components involved in these processes include trans-
porters (such as CTR1 for copper and ZIP for zinc), channels
(such as voltage gated calcium channels), and pumps (such as
calcium-ATPase), which allow the transport of metal ions across
biological membranes; endocytosis of protein:metal complexes
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(such as transferrin:iron) into the cell and chaperones (such asCCS
for copper), which escort metals into the cell. These, and other,
processes involved in the highly complex process of metal trafﬁck-
ing and homeostasis have been critically reviewed elsewhere (Ba
et al., 2009) and will not be discussed here.
Such a high level of control at many cellular “levels” is essen-
tial in limiting potentially deleterious interactions of redox active
transition metal ions, which are implicated in the pathogene-
sis of a number of disorders including AD (Sayre et al., 1999;
Smith et al., 2007). The involvement of metal ions in disease
extends the breadth from being involved in creating an adverse
cellular milieu (which among other things, may promote cell
death through the activation of particular pathways that lead
to degeneration) through to direct involvement in the genera-
tion and toxicity of the principle toxic moiety in diseases such
as AD.
Given the compelling evidence for the critical role of cop-
per and zinc in both precipitating and potentiating AD (Adlard
and Bush, 2006; Adlard et al., 2009; Duce et al., 2011), attempts
to modulate the metal:AD interaction are an emerging thera-
peutic strategy. Genetic studies in various mouse models of AD
supports this notion. Lee et al. (2002), for example, demon-
strated that the ablation of the synaptic zinc transporter [zinc
transporter 3 (ZnT3); Palmiter et al., 1996; Cole et al., 1999] in
Tg2576 mice [a mutant human amyloid precursor protein (APP)
over-expressing AD mouse model] resulted in a loss of vesicu-
lar zinc in glutamatergic synapses and a concomitant reduction
in both Aβ plaques (number and/or percentage area occupied
within the brain) and insoluble Aβ burden. These data are sup-
ported by more recent reports that have clearly deﬁned a role
for zinc in synaptic pathways critically affected in AD (Adlard
et al., 2010), and indeed, the 3xTg mouse model of AD has shown
a gender-dependent alteration in vesicular zinc-related plastic-
ity (Nakashima et al., 2010). Deshpande et al. (2009) have also
demonstrated that Aβ oligomers are attracted to zinc emanating
from the glutamatergic synapse, and that this can then occlude
the NMDAR2B receptor and thus affect downstream signaling
pathways. In another study, by Phinney et al. (2003), TgCRND8
mice (a double mutant human APP over-expressing AD mouse
model) were crossed with tx J mice to generate mice with a muta-
tion in the transport protein (ATPase7b) that loads copper into
secretory vesicles (Lutsenko and Petris, 2003). This resulted in
elevated brain copper levels and a concomitant signiﬁcant reduc-
tion in the number of dense cored plaques in the cortex and
hippocampus.
While such genetic approaches are unlikely to become a ther-
apeutic option for the treatment of AD, it does highlight the
relevance of targeting metal ions in this disease. In addition to the
modulation of endogenous factors such as these and others (such
as metallothioneins), there have been numerous attempts at mod-
ulating metal levels within the CNS through dietary modiﬁcation
and pharmacological intervention.
Utilizing the APP23 mouse line (a mutant human APP over-
expressing AD mouse model), Bayer et al. (2003) demonstrated
that 3 months of elevated dietary copper intake was sufﬁcient to
remediate the copper deﬁcit present in the APP23 mouse model,
and to also lower Aβ burden. Similarly, increasing the dietary
intake of zinc in both the TgCRND8 (for 5 months) and Tg2576
(for 11 months) mice (Linkous et al., 2009) resulted in a reduction
in Aβ burden and a histological reduction in plaque size (which
was also paradoxically associated with impaired performance on
behavioral assessments of cognition). These data are consistent
with earlier work (Stoltenberg et al., 2007) demonstrating that
mice over-expressing mutant human APP and Presenilin 1 (PS1;
APP/PS1) maintained on a zinc-deﬁcient diet for 3 months had
a signiﬁcant elevation in Aβ plaque burden and a histological
increase in plaque size.
Cumulatively, these data highlight the dynamic nature of AD-
like pathology in the various mouse models and importantly,
identify a critical role for metal ion homeostasis in the patho-
genesis of disease. This complexity, however, is exacerbated by the
apparent interaction between metals such as copper and zinc. A
recent study (Railey et al., 2011), for example, demonstrated that
the cognitive deﬁcits observed in zinc-supplemented mouse mod-
els of AD can be overcome by parallel copper supplementation.
Furthermore, high levels of dietary zinc can inhibit the intestinal
absorption of copper (Sandstead, 1995) and lower cortical copper
levels (Flinn et al., 2005),whileWilson’s disease (a copper-overload
disorder) is effectively treated with dietary zinc (Sinha and Taly,
2008). Thus, any biological effects derived from the modulation of
a particular metal species may, in fact, be affected by a consequent
alteration in a different metal ion.
These data also suggest that a singular mechanistic approach
is unlikely to afford the long-term beneﬁt required for a truly
effective and disease modifying therapeutic – as in the brief
discussion above, it is clear that homeostatic deﬁcits in metal
ions need to be rectiﬁed, but at the same time, the elimination
of metals from discrete cellular targets/zones (e.g., the synapse)
also modiﬁes the progression of disease [but this may come
at a cognitive cost – as is implied from the data showing that
reductions in synaptic zinc levels reduce plaque burden in Tg
mice (Lee et al., 2002), but also result in severe cognitive deﬁcits
when ablated in WT animals (Adlard et al., 2010); the cogni-
tive effect of ZnT3 ablation in Tg mice has yet to be assessed].
Thus, highly targeted approaches that either increase or decrease
a particular metal ion may be inherently confounded. In this
regard, metal chaperones (which have also variously been referred
to as “ionophores” and “metal-protein attenuating compounds”)
may represent the “sweet spot” of metal-targeted therapeutics for
AD because they foster the maintenance and/or restoration of
metal ion homeostasis which then impacts a raft of “healthy” and
“pathological” cellular pathways that ultimately promotes “nor-
mal”function. Such context-dependentmodulationof metal levels
may prove critical for long-term therapeutic strategies that target
metal ions.
METAL CHAPERONES: A NOVEL THERAPEUTIC STRATEGY
FOR AD?
A number of metal-targeted approaches have been employed in
both preclinical animal studies and human clinical trials, and we
have critically reviewed these recently (Duce et al., 2011). How-
ever, one of the more promising chaperone candidates that has
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an evolving literature, particularly surrounding its mechanism of
action, is PBT2 (Prana Biotechnology).
Utilizing both Tg2576 and APP/PS1 animals, we have pre-
viously demonstrated that varying PBT2 treatment paradigms
(acute and chronic dosing) result in signiﬁcant decreases in
histological Aβ plaque burden, a signiﬁcant decrease in biochem-
ical Aβ load and a signiﬁcant decrease in interstitial ﬂuid Aβ
levels (Adlard et al., 2008). Further to this, the other side of
the “Alzheimer’s equation” is the loss of functional tau result-
ing from its hyperphosphorylation (and subsequent formation
of intracellular neuroﬁbrillary tangles), and to this end, we have
demonstrated that PBT2 signiﬁcantly decreases the levels of phos-
phorylated tau in animal models of AD (Adlard et al., 2008). Thus,
the compound has the potential to modulate both major hallmark
pathologies in the AD brain. These pathologies, while central to
the clinical diagnosis of AD and also reported to be critical to
the pathogenesis of disease, are ultimately important more for
their downstream effects on normal brain function/cellular path-
ways. In this regard, AD has often been referred to as a disease
of disconnection, where the loss of synaptic connections gradu-
ally erodes memory and other higher order cognitive functions
to drive the symptomatic presentation of disease (potentially as
a direct consequence of the deposition of Aβ). If a therapeutic
were to have an effect on Aβ or tau in the absence of any sub-
sequent downstream improvement in critical disease measures
(e.g., memory) and their associated anatomical correlates (e.g.,
synapses and dendritic spines), then the approach would be fun-
damentally limited and not provide any level of long-term disease
modiﬁcation. In this respect, we have demonstrated that PBT2
signiﬁcantly increases synaptophysin levels (a surrogate marker
for synapses) in transgenic mouse models of AD (Adlard et al.,
2008), in addition to restoring hippocampal dendritic spine den-
sity in both young and old transgenicmousemodels of AD (Adlard
et al., 2011). These effects occurred in conjunction with a restora-
tion in the levels of key synaptic proteins involved in cognition,
such as NMDA receptors as well as elements of the BDNF path-
way. Preliminary in vitro evidence supported the notion that PBT2
acts in a metal-dependent manner to regulate neurite outgrowth
and NMDA receptor protein levels (Adlard et al., 2011), and this
has been further deﬁned in a more recent study examining the
mechanisms of action of PBT2 (Crouch et al., 2011), as described
below.
PBT2 treatment of SH-SY5Y cells has been shown to result in
a metal-dependent phosphorylation of glycogen synthase kinase
3 (GSK; which may occur via an inhibition of the phosphatase
calcineurin, whose other substrates such as CREB and CaMKII
are also modulated by PBT2) which subsequently inhibits the
activity of GSK, one of the major tau kinases in the brain (Lei
et al., 2011). Importantly, the metals translocated into the cell
by PBT2, which can also activate numerous other cellular path-
ways involved in neuronal and synaptic health, can be effectively
“sourced” from protease-resistant extracellular Aβ:Zn aggregates,
which themselves then become subject to degradation by endoge-
nous clearance mechanisms such as matrix metalloproteases after
the metal is removed from the Aβ. This highlights the biological
relevance of the activity of PBT2, and also clearly demonstrates
the notion that PBT2 has multiple metal-dependent activities that
affect several different key aspects of the AD cascade, including the
triad of Aβ, tau and cognition.
Cumulatively, these speciﬁc effects on disease-related path-
ways and endpoints are likely to represent the major underlying
mechanism for the rapid PBT2-dependent reversal of the cog-
nitive impairment observed in vivo (Adlard et al., 2008). These
in vitro and in vivo studies showing potential efﬁcacy for this metal
chaperone in targeting both biomarkers and the major sympto-
matic feature of disease are supported by an emerging clinical
literature.
The safety and efﬁcacy of PBT2 was assessed in a small [n= 29
placebo; n= 20 low dose PBT2 (50 mg/day); n= 29 high dose
PBT2 250 mg/day] 12 week, double-blind and placebo-controlled
trial (Lannfelt et al., 2008). The safety proﬁle for PBT2 was
favorable and it also showed a signiﬁcant modulation of bio-
markers and clinical endpoints. Speciﬁcally, PBT2 treatment sig-
niﬁcantly decreased CSF levels of Aβ1–42 in a dose-dependent
manner, as compared to the placebo group. Cognitive testing,
which included ADAS-cog, MMSE and a neuropsychological test
battery (NTB), revealed that the high dose treatment group had
a signiﬁcant improvement in executive function compared to the
placebo-treated group. Further analysis of the cognitive data (Faux
et al., 2010) revealed that, based upon a ranking analysis, the
high dose treatment group had a signiﬁcantly higher propor-
tion of patients showing improvement on the NTB composite
z-score and executive factor z-score as compared to the placebo
group, with the ADAS-cog data also approaching signiﬁcance
(p= 0.056).
There are ongoing AD trials with PBT2, with a 12 month Phase
II imaging trial currently recruiting. This study is designed to assess
the anatomical correlates of PBT2 treatment, speciﬁcally look-
ing at the effect of PBT2 on Aβ plaque load in the living human
brain, as well as to consolidate the evidence for longer-term cogni-
tive beneﬁts of this compound (www.pranabio.com). Much larger
Phase III trials will then be required to deﬁnitively establish the
efﬁcacy of PBT2 for the treatment of AD. This is a signiﬁcant
hurdle for any new compound to pass, and only in testing will
it be established if PBT2 is any different to the other promising
Phase II candidates that have not met expectations in Phase III
trials.
CONCLUSION
Taken together, these data provide compelling evidence for the
efﬁcacy of metal-targeted approaches in the treatment of AD, and
also speciﬁcally point to the use of metal chaperones as being
one particularly effective strategy. In this review we have high-
lighted the reported activities andpotential for PBT2,an 8-hydroxy
quinoline compound. A recent screen of 200,000 compounds
in a yeast model system identiﬁed this class of compound as
being particularly effective at preventing proteotoxicity. It was also
identiﬁed that different 8-hydroxy quinolines exhibited distinct
activities on metal ion homeostasis and metalloprotein activi-
ties (subtle changes to the molecular backbone evinced signiﬁcant
changes in biological activity), implicating the therapeutic poten-
tial for different 8-hydroxy quinolines against a range of different
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neurodegenerative disorders (Tardiff et al., 2012). Thus, while
metal chaperones such as PBT2 may prove efﬁcacious in the treat-
ment of AD and a host of other disorders that are characterized
by metal ion dyshomeostasis, it will remain crucial to identify the
optimal metal chaperone for a given disorder, and to also treat at
the right stage of disease.
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